(Q33761456)

29 July 2017

1 reference

title

Counting the costs of drug-related adverse events (English)

1 reference

29 July 2017

White TJ

1

1 reference

29 July 2017

Arakelian A

series ordinal

2

1 reference

29 July 2017

Rho JP

series ordinal

3

1 reference

29 July 2017

publication date

1 May 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

15

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

445-458

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199915050-00003

29 July 2017

exact match

0 references

cites work

Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation

1 reference

12 December 2020

Drugs and adverse drug reactions: how worried should we be?

1 reference

12 December 2020

Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues

1 reference

12 December 2020

Comparative cost effectiveness of gentamicin and tobramycin

1 reference

12 December 2020

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

12 December 2020

Drug-related hospital admissions

1 reference

12 December 2020

Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs?

1 reference

12 December 2020

The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis

1 reference

12 December 2020

Cost of medication-related problems at a university hospital

1 reference

12 December 2020

What is the cost of nephrotoxicity associated with aminoglycosides?

1 reference

12 December 2020

Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres

1 reference

12 December 2020

Evaluation of excessive anticoagulation in a group model health maintenance organization

1 reference

12 December 2020

Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

1 reference

12 December 2020

Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury

1 reference

12 December 2020

Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit

1 reference

12 December 2020

Incidence and cost of hospital admissions secondary to drug interactions involving theophylline

1 reference

12 December 2020

Preventing adverse drug events in hospitalized patients

1 reference

12 December 2020

Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs.

1 reference

12 December 2020

A pharmacoeconomic model to evaluate antibiotic costs.

1 reference

12 December 2020

Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs.

1 reference

12 December 2020

Adverse events and cost savings three years after implementation of guidelines for outpatient contrast-agent use.

1 reference

12 December 2020

Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy

1 reference

12 December 2020

Nonnarcotic analgesics: prevalence and estimated economic impact of toxicities

1 reference

12 December 2020

Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.

1 reference

12 December 2020

A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs

1 reference

12 December 2020

Economic costs of theophylline toxicity

1 reference

12 December 2020

Cost-effectiveness analysis of the use of digoxin immune Fab(ovine) for treatment of digoxin toxicity

1 reference

12 December 2020

Economic impact of digoxin toxicity.

1 reference

12 December 2020

Human and non-financial costs of hospital-acquired infection

1 reference

12 December 2020

Assessing the economic value of a new antidepressant. A willingness-to-pay approach

1 reference

12 December 2020

The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group

1 reference

12 December 2020

A practical guide for calculating indirect costs of disease

1 reference

12 December 2020

Incidence and preventability of adverse drug events in hospitalized adults

1 reference

12 December 2020

Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units

1 reference

12 December 2020

Economic outcomes and costs in the treatment of schizophrenia

1 reference

12 December 2020

Antibiotic-associated diarrhoea. A costly problem

1 reference

12 December 2020

Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective

1 reference

12 December 2020

Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.

1 reference

12 December 2020

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

12 December 2020

Increased length of hospital stay due to Clostridium difficile associated diarrhoea

1 reference

12 December 2020

Drug-Related Morbidity and Mortality

1 reference

12 December 2020

Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.

1 reference

12 December 2020

1 reference

12 December 2020

The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population.

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective

1 reference

12 December 2020

Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin

1 reference

12 December 2020

Time to act on drug safety

1 reference

12 December 2020

Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group

1 reference

12 December 2020

Evaluation of theophylline overdoses and toxicities

1 reference

12 December 2020

The economic burden of depression in 1990.

1 reference

12 December 2020

10.2165/00019053-199915050-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1035985013

0 references

1 reference